FDA Approves Two New Indications and Dosage Form for Pembrolizumab
In this installment of Oncology Drug Updates, updates to FDA approvals for pembrolizumab in the treatment of lung cancer and RCC are highlighted.
Key Advances in Oncology, 2018
Our team reviews the most important advances in oncology in 2018, including those in breast cancer, hematologic cancers, lung cancer, immunotherapy, and more.
Oncology Conference Highlights, Q4
Our team reviews 2018 conference highlights in oncology care, including studies from ASH, SABCS, and SIO.
The Long-Term Outlook for Mogamulizumab in Previously Treated Cutaneous T-Cell Lymphoma
The results of a follow-up analysis to the phase III MAVORIC study were presented at the ASH 2018 Annual Meeting & Exposition.
Biosimilars: New Avenues for the Practicing Oncologist Treating Breast Cancer
Research presented this week at ESMO studied the efficacy of biosimilars to trastuzumab compared with the reference product in breast cancer.
2 Clarke Drive Cranbury, NJ 08512